Novopyxis
Cambridge, US · Founded 2013 · Delaware corporation · 1 known investors
Find your way into Novopyxis
NovoPyxis applies mathematics and physics principles, including knot theory and fluid dynamics, to drug design and delivery, predicting protein structures of uncrystallized targets and designing peptide agonists. Its work includes a cardiomyopathy drug candidate and a transdermal device for delivering large-molecule drugs into skin.
Founders & leadership
DV
Daniel VannoniNamed on SEC filing
RS
MG
Madhavi GaviniNamed on SEC filing
Investors · 1
Reported raises · per SEC filings
Form D private placements$855.9K disclosed across 2 rounds · 2014–2017
▶$512.9KraisedJul 2017 · 19 investors · BiotechnologyRule 506(b)
▶$512.9KraisedJul 2017 · 19 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Daniel VannoniDirector
- Raja SrinivasDirector
- Madhavi GaviniExecutive Officer, Director
- Offering amount
- $512.9K
- Amount sold
- $512.9K
- First sale
- Apr 2017
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
▶$343KraisedJul 2014 · 12 investors · Biotechnology
▶$343KraisedJul 2014 · 12 investors · Biotechnology
Officers, directors & promoters on the filing
- Raja SrinivasDirector
- Madhavi GaviniExecutive Officer, Director
- Daniel VannoniExecutive Officer, Director
- Offering amount
- $400K
- Amount sold
- $343K
- First sale
- Jul 2014
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 04
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $496.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Novopyxis do?
- NovoPyxis applies mathematics and physics principles, including knot theory and fluid dynamics, to drug design and delivery, predicting protein structures of uncrystallized targets and designing peptide agonists. Its work includes a cardiomyopathy drug candidate and a transdermal device for delivering large-molecule drugs into skin.
- Who are Novopyxis's investors?
- Novopyxis's investors include Bantam Group.
- How much funding has Novopyxis raised?
- Novopyxis has disclosed $855.9K raised across 2 rounds.
- Where is Novopyxis headquartered?
- Novopyxis is headquartered in Cambridge, US.